Inventor · disambiguated record
Matthew Welsch
Also filed as: WELSCH MATTHEW · WELSCH MATTHEW ERNEST
14 granted patents·5 pending applications·46 citations·filing 2013–2024
89Inventor score
Files withBIOMEA FUSION INC5KLEO PHARMACEUTICALS INC5BIOMEA FUSION LLC3UNIV COLUMBIA2VYERA PHARMACEUTICALS LLC2
Top patents by PatentIndex Score
19 records- 0194US11702421B2Substituted pyridines as irreversible inhibitors of menin-MLL interactionBIOMEA FUSION LLC·Filed 2021·Granted Jul 18, 2023·6 cites·4 claims
- 0293US11084825B2Substituted pyridines as irreversible inhibitors of menin-MLL interactionBIOMEA FUSION LLC·Filed 2019·Granted Aug 10, 2021·19 cites·26 claims
- 0390US11174263B2Inhibitors of menin-MLL interactionBIOMEA FUSION LLC·Filed 2019·Granted Nov 16, 2021·11 cites·25 claims
- 0489US9695133B2Quinazolinone-based oncogenic-RAS-selective lethal compounds and their useUNIV COLUMBIA·Filed 2013·Granted Jul 4, 2017·8 cites·28 claims
- 0583US12116371B2Substituted pyridines as irreversible inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Oct 15, 2024·0 cites·14 claims
- 0682US2024376112A1N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOFBIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 0780US12077544B2Irreversible inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Sep 3, 2024·0 cites·20 claims
- 0876US12275739B2Inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Apr 15, 2025·0 cites·21 claims
- 0971US10774073B2Compositions and methods for treating infectionsVYERA PHARMACEUTICALS LLC·Filed 2017·Granted Sep 15, 2020·1 cites·21 claims
- 1071US9926293B2Multivalent RAS binding compoundsUNIV COLUMBIA·Filed 2016·Granted Mar 27, 2018·1 cites·10 claims
- 1170US2025243216A1Cd16a binding agents and uses thereofKLEO PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1268US11845753B2Inhibitors of menin-mll interactionBIOMEA FUSION INC·Filed 2021·Granted Dec 19, 2023·0 cites·20 claims
- 1366US12162892B2CD16a binding agents and uses thereofKLEO PHARMACEUTICALS INC·Filed 2022·Granted Dec 10, 2024·0 cites·11 claims
- 1458US11572370B2CD16A binding agents and uses thereofKLEO PHARMACEUTICALS INC·Filed 2019·Granted Feb 7, 2023·0 cites·16 claims
- 1558US11530198B2Compositions and methods for treating infectionsVYERA PHARMACEUTICALS LLC·Filed 2020·Granted Dec 20, 2022·0 cites·18 claims
- 1646US2020390895A1Universal abt compounds and uses thereofKLEO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1746US2023028880A1Cd38-binding agents and uses thereofBIOHAVEN THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 1845US2023128688A1Directed conjugation technologiesKLEO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1939US10780084B2Antibody-recruiting molecules for the treatment of cancerUNIV YALE·Filed 2017·Granted Sep 22, 2020·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when Matthew Welsch files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →